BioOutsource Opens New Facility in Glasgow

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
Volume 11
Issue 8

The investment doubles the company’s capacity to meet increasing demand for its biologics contract testing and biosimilar characterization services.

BioOutsource, part of Sartorius Stedim Biotech Group, has opened a new facility in Glasgow. The investment follows the increasing demand for the company’s biologics contract testing and biosimilar characterization services. The new facility doubles BioOutsource’s capacity for future growth and will create approximately 50 new jobs for scientific and technical professionals in the next six months, according to the company.

Source: BioOutsource

Articles in this issue
Figures1-New-1438610917643.gif
CDMOs Move Slowly with Expansion Plans
Accelerating Continuous API Synthesis
Accelerating Continuous API Synthesis
BioOutsource Opens New Facility in Glasgow
Needle in the Haystack, or Rembrandt in the Attic? Drug Repurposing's New Strategy
Silicone Rubber Pieces Spur Recall of Teva Product
Baxter Recalls IV Solution for Container and Particulate Issues
Indian API Manufacturer Cited for Recordkeeping Failures
Xcelience Makes Investment in Powdersize
FDA Issues Quality Metrics Draft Guidance Document for Comment
EMA Issues Guideline on Fast Tracking Drugs for Unmet Needs
SafeBridge Updates Potent API and Drug Manufacturer Status
Capsugel Expands Capabilities at its Edinburgh Facility
DPx Holdings Sells Fine Chemicals Business
World Courier Receives UK Wholesale Distribution Authorisation
CSafe Adds Service Center for Controlled-Temperature Shipping in Switzerland
Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content
INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

Patrick Lavery;Feliza Mirasol
April 1st 2025
Article

William Wainwright, business development manager at Iwata Label USA, discusses the practical security benefits of functional labels at INTERPHEX 2025.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Culture Biosciences Opens INTERPHEX 2025 with Launch of Cloud-Integrated Mobile Bioreactor

Patrick Lavery
April 1st 2025
Article

The company said the Stratyx 250 is the first bioreactor of its kind to offer biotech companies a combination of automation, remote process control, and flexibility.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Facing the Latest Patent Cliff

Mike Hennessy Jr.
April 1st 2025
Article

Over the course of the next five years, the bio/pharma industry is expected to see the patents of multiple blockbuster drugs expire, impacting some key industry players.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

FDA CBER Director Peter Marks Resigns

Susan Haigney
March 31st 2025
Article

Marks called out an ‘assault’ on truth and science in his resignation letter, which has sent the bio/pharmaceutical industry reeling.